Sensex

up-green-arrow

Nifty

up-green-arrow

USDINR

down-red-arrow

GBPINR

down-red-arrow

EURINR

down-red-arrow

Company News

J B Chemicals & Pharmaceuticals Ltd
JB Chemicals Q1 PAT jumps 14% YoY to Rs 202 cr
Jul 31,2025
Profit before tax (PBT) stood at Rs 271.61 crore in Q1 FY26, rising 13.25% from the Rs 239.84 crore recorded in Q1 FY25.

In Q1 FY26, operating EBITDA stood at Rs 330 crore, up 13%, compared with Rs 292 crore posted in the same quarter last year. Operating EBITDA margin stood at 30.2% in Q1 FY26 as against 29% in Q1 FY25.

Nikhil Chopra, CEO and whole-time director of JB Pharma, stated, “JB continues to be the fastest-growing domestic pharma company amongst the top 25 organizations as per IQVIA MAT Jun’25 data. The domestic business recorded approximately 14% value growth. This was driven by acute and chronic segments, including our ophthalmology portfolio.

Our major brands & their franchises are also performing well. The CDMO business momentum is likely to be sustained in coming quarters. Our operating EBITDA margins crossed 30% for the first time, which highlights the results of our strategy of focusing on profitable growth.

Going forward, we will maintain focus on driving topline growth, cost optimization, and organizational efficiencies. I am confident that the organization will continue to perform well, with our domestic and CDMO segments leading the way on growth and profitability. We have all the necessary building blocks in place for sustainable growth in the coming years.”

JB Chemicals & Pharmaceuticals manufactures a wide range of pharmaceutical formulation specialties, radiodiagnostics, APIs, and intermediates.

Shares of JB Chemicals & Pharmaceuticals fell 1.67% to Rs 1,753.15 on the BSE.

Attention Investor :

"Prevent unauthorised transactions in your account ; Update your mobile numbers/email IDs with Us. Receive information of your transactions directly from Exchange on your mobile/email at the end of the day” - Issued in the interest of Investors"

"KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary."

"No need to issue cheques by investors while subscribing to Equity IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."

A Muthoot M George Enterprise